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ةصلاخلا 
ةيفلخ  ثحبلا: ِتٕهخ ِضشم ٓف وَذنا ِمقىن هٕٕسٕئشنا هٕببسنا ّنإ وذنا شقف حّحُصتن ٓهجىمناهسحت ٓكن وَذنا  عىمنَ هٕجسكَلأا مقو تٕهباق
.ٓهجىمنا وذنا باعخ تبسو مٕهقتب ٓئاعُنا داذسولاا ثَذحانا ممحنا .لُصحنا دساَ نُكٕس ْذٔذح 
: فذهلا  ِتساسذنا يزٌ فذٌ ّنإا توساقمن.ذٔذحنا دساُغ فهتخم ِجلاع ِةءافكَ ناملأ 
ةيجهنملا ؛ نُسمخ َ ناىثا هٕتعُمجم ّنإ اُمّسق طٔشم ِجلاعب  ِتجناعمهن ،هٕتَٔاستمDeferoxamine  عم كشتشمنا ساقع  
Deferasiro  ّهع َ   Deferasirox.يذحُنتٔشجأ تساسذنا  سارا هم ةشتفهن2102  غابش تٔاٍو تٔاغن2102 َ هٕتشفنا صُحف تهمع.
.توساقمناَ تعباتمهن مئاسُك ّهكناَ ذبكنا فئاظَ 
ِجئاَتنلا :  اتهك تتبثأتمظوأ  جلاعنانأ  ِمصم ٓف هٕتٔشفنا غُبٌ َتجسد نإ. ِتُٔهكنا ََأ ِتٔذبكنا ِتفٕظُنا ّهع َّداعم شٕثأت لا وذنا اذج ّهعأ
 ِجلاعب Deferoxamine_ Deferasiroxنا.كشتشم 
اجاتنتسلا :  كشتشمنا جلاعنا Deferoxamine__Deferasirox هِم ِلُبقمنا ُِتسمناب ِمصمنا ٓف هٕتٔشفنا تبسو ّهع واٌ شٕثأت ًن
.ِناملأا 
يصوتلا: تا   جلاعنا اىمآ ًاماظو ناَك كشتشمنا ِةذٕج ةءافكب ًنامعتسا هكمم نّظشم ٓهجىمنا وذنا شقف .ذئازنا ْذٔذحنا ِممحنا َْر 
 
Abstract 
Background: the two main reasons for blood transfusion in sickle cell disease are to correct anemia so 
that the oxygen-carrying capacity of the blood is improved, and to treat or prevent painful 
vasoocclusive by lowering the proportion of sickle cell hemoglobin. Iron over load will be  evitable. 
Aim: The aim of this study is to asses safety and efficiency of different chelation therapy. 
Patients and method: Fifty two patients divided in to two equal group, for treatment by combined 
Deferoxamine-Deferasirox therapy and on Deferasirox alone. 
Results: both drug regimens proved to have no adverse effect on hepatic or renal function. The degree 
of descend of serum ferritin is significantly higher with combined Deferoxamine-Deferasirox therapy. 
Conclusion: combined chelating agents have significant effect on serum ferritin, with acceptable  level 
of safety. 
Recommendation: combined therapy was safe regime and can be used with good efficacy for patients 
with iron over load. 
Key wards: sickle cell disease. Iron overload. Serum ferritin 
 
INTRODUCTION: 
       Advances in molecular and cellular biology have broadened our manifestations of 
sickle cell disease(SCD) can be attributed to vaso-occlusion and chronic 
hemolysis
.(1)
the use of blood transfusion in this disease is increasing, and blood 
transfusion therapy is now considered standard care for primary and secondary stroke 
prevention in children with SCD
.(2)
 
The use of transfusion therapy in SCD is increasing because of recent evidence 
indicating its ability to prevent organ injury and improved the outcome of 
complications
(3).
 
the body has no active mechanism to excrete accumulated iron. Iron over load cause 
tissue damage such as heart failure, liver disease ,endocrine disturbance which could 
cause eventual death failure .Transfusion is necessary  with the aim of reducing the 
proportion of hemoglobin S to less than 30% of the total while not raising the total 
hemoglobin _10 gm/dL. Automated red cell exchange
(4,5)
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Recent evidence suggests that serial serum ferritin in steady state correlate 
significantly with liver iron concentration through magmatic resonant imaging(MRI) 
and can be cost effective readily available tool for iron over load monitoring in SCD 
particularly in regions with limited resources and high disease burden.      
Liver iron content has been accepted as the most accurate quantitative means of 
determining whole-body iron concentration. However, liver biopsy is not indicated for 
routine assessment due to its invasive nature. 
(5).
 
For many patients with chronic anemia's, regular red blood cell transfusions are 
lifesaving. However, with each unit of transfused blood, 200–250 mg of iron is 
transferred to the patient. There are no natural means of removing excess iron from 
the body and so iron gradually accumulates (over5–10 years) to toxic levels that affect 
major organs such as the heart and liver.1 This condition, commonly known as iron 
overload or transfusion hemosiderosis, can cause organ damage anddeath.2 Currently 
the only way to prevent this is by long-term chelation therapy.
(6)
 
The first oral iron chelator introduced to the US was Deferasirox (DFX), which is 
additionally licensed in Europe and other regions for the treatment of iron overload. 
Its long half-life of 11–19hours maintains plasma levels within the therapeutic range 
over a24-hour period, allowing for a convenient once-daily oral administrationand 
offering a viable option over Deferoxamine (DFO)and its associated problems with 
compliance.
(7)
 
Deferoxamine  has until now been considered the treatment of choice for patients with 
chronic iron overload
.
 In recent years multiple different iron chelating regimens were 
used, which include: monotherapy, combined and alternative sequential regimens. 
(8)
 
Deferasirox is an orally activeiron-chelating agent that binds iron in a 2:1 ratio and is 
primarily excreted in feces. It is given oncedaily as an oral suspension (usually in 
water or fruitjuice) at a dose of 10–30 mg/kg.47 
The ease of administration of Deferasirox (oral) compared with Deferoxamine 
(infusion) might improve patient adherence to therapy7 and, if effective, may also 
improve quality and quantity of life.
(9)
 
Compliance with the administration of parental Deferoxamine therapy has proven 
challenging to all groups of patients with transfusion over load.
(10)
In recent years 
multiple different iron chelator regimens were used, which include monotherapy, 
combined and alternative sequential regimens
(11)
. The aim of study is to assess the 
safety of combined Deferoxamine-Deferasirox therapy for patients with sickle cell 
disease. 
PATIENTS AND METHOD: 
This prospective comparative study was performed in Najaf thalassemia center, 
from March 2012,untilend of February 2013patients enrolled was 52 of sickle cell 
patients. Twenty six were chosen to have (DFX) therapy, randomly by way (3:1) 
sequence of their files .Hemoglobin level of all patients was maintained between (8.6-
9.8gm|dl).starting oral dose was 30\mg |kg day, before breakfast, increased gradually 
by 5mg|kg|month,till dose of 40 mg|kg|day. Twenty six patients were already on 
(DFO)therapy on dose of 20 mg|kg|day, subcutaneously infused by special portable 
device,12 hour a day, five days a week. when they were chosen to enter this study, 
their therapy changes to combined (DFO) 20mg\kg\day infusion two days per week, 
and (DFX) in dose of 40 mg\kg\day seven days per week. Written consents was taken 
from patients or parents who chose combined therapy, and the draw back of each 
drugs were clarified for all patients in both group. Serum ferritin level of those who 
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were on DFX alone at the start was(4692-12600mcg|l),while ferritin level of those 
who chose combined therapy, at the start, was(5268-9035mcg|l). For all patients Cell 
Blood Count (CBC), serum ferritin by miniuvidus, alanine aminotransferase (ALT), 
blood urea, serum creatinine and prothrombine time were tested. Patients were 
excluded if they had a serum creatinine above the upper limit of normal, or if they 
have positive serological test of hepatitis. After collecting data, statistical analysis was 
performed by SPSS 16.0.2. Differences were considered significant at PV <0.05 
RESULTS 
 For those patients who chose continuation on combined DFX-DFO therapy 
median serum ferritin level at the start was6337mcg\l range (5268-9035)l,at the end of 
first year median ferritin was 4850mcg\l ,rang(4515-8114)and the paired deference 
was 1480mcg\l,p-value is significant( 0.012).(table2).sTwenty six patients who were 
on DFX alone ,at the point of the end their median serum ferritin decline from 
7351mcg\l, range(6326-12600mcg\l) to the level of6379 mcg\l , range(3406-11869)\\ 
paired deference between the two pints was 982mcg\l, p value is significant 
(0.0124)(table 1).It is apparent that there washigher  and significant descent in serum 
ferritin for patients on combined therapy- p-value is significant,(1480 versus 982 
mcg\l)Median aspartate amino transferase (ALT),and aspartate amino transferase was 
maintained with in safe level between the reading at the start and at the end of the 
study(86±16 iu\lat the start and 66±9iu\l at the end for ALT) and (62±12 ---83±8 for 
ASTiu\l) respectively, without any abnormal surge,(table1).p-value was more than 
0.05 for both group. patients on combined therapy, also there was no significant 
deference in the level of ALT and AST noticed at the end of the study(table2). 
Table 1 ;liver enzymes ,renal test changes for patients on Deferasirox alone 
P 
value 
Range  End –mean Start –mean Range Test 
,012 3406-11869 6379mcg \l 7351 6326-12600 S F 
NS 23 -30    26.4 30      24 – 32 B U 
NS  0.52      0.42     0.3 – 0.6 S C  
NS 57 -75   66±9 IU \ L 86±16 70 – 102 ALT 
NS 75 – 91 83±8 IU \ L 62±12   50 -74   AST 
NS  13 SEC     12 SEC  PT  
 
Table 1 demonstrate  that there was significant reduction in the level of serum 
ferritin, for patients who chose oral chelation, without  significant elevation in  liver 
enzymes and renal function tests. 
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Table 2 ;variables over one year for patients on combined therapy 
P value Range  End –
mean 
Start –mean Range Test 
0.001 4515-8114 4850 6337 mcg \ l 5269-9035 S F 
NS 24-31 26.5 27.5mg \l 25-34 B U 
NS 0.4-0.7 0.5 0.4 mg \ l 0.3 –O,6 S C  
NS 75 -131 89±  11 91±  8 IU \L 78-104 ALT 
NS 67- 109 84±13 78±11 IU \L 62- 123 AST 
NS  13 14Sec  PT  
 
Table 2 clarified that, combined therapy still maintained safety within 
acceptable range, with remarkable reduction in level of serum ferritin, with significant 
variation from  decline for those on oral Deferasirox. Renal function test was assessed 
for time of the study by blood urea and serum creatinine, for both group of patients 
reading remain much lower than permissible level of safety (table 1). For those who 
were on combined therapy, also there was no significant deference in the level of 
ALT noticed at the end of the study (table2). For prothrombine time(PT) and aspartate 
aminotransferase(AST) in both group all reading were maintained with in permitted 
levels ,and there was no significant surge  noticed 
 
DISCUSSION: 
Studies have shown that regular transfusions in children with SCD can 
significantly reduce the risk forprimary and secondary stroke, hospitalizations, vaso-
occlusive events, acute chest syndrome, and growth failure.
(12,13)
The overall 
compliance of our patients was very promising , since no one of them escape the 
treatment program and follow up for the total one year period. Compliance with the 
administration of parentalDeferoxamine therapy has proven challenging to all groups 
of patients with transfusion over load
.13)
Result of our study at the point of the end 
clarified as shown in table(1))that serum ferritin was decreased by significant 
proportion (966mcg\l) in those who were on oral DFX this study and result consistent 
with global new idea about new oral chelator DFX. Deferasirox is effective oral iron 
chelator with a long half-life, which could be used as monotherapy. It could provide 
constant gap-free chelation coverage with a single daily dose, and  efficient and 
selective role on organs such as heart and live 
(17-20)
. Deferasirox could produce an 
acceptable 24 hours iron chelator coverage. However, the efficacy on the high iron 
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overload is questionable. It could not achieve a negative iron balance even with 
highest recommended dose, which might cause severe side effects. So, none of iron 
chelator drugs could provide all therapeutic goals. The iron chelator Deferoxamine 
(Desferal [DFO, Novar-tis Pharma AG, Basel, Switzerland]) has had a dramatic effect 
on long-term survival and morbidity of thalassemia patients. It has established an 
excellent safety andefficacy profile for pediatric patients through several de-cades of 
clinical use.
(14)
 
Recent evidence indicated thatcontinuous Deferoxamine infusions may reverse 
iron-induced heart failure. Deferoxamine, however, haspoor oral bioavailability and a 
short half-life, necessitating administration as an 8- to 12-hour overnight 
subcutaneous infusion 5 to 7 days per week or as a 24-hourintravenous infusion
.
 Such 
regimens are extremely burdensome and often lead to poor compliance, particularly in 
adolescent patients
.(16)
 Those who do not comply with their treatment are usually 
undergo chelation in-adequately, which has a significant impact on survival. This is 
especially a concern for iron-overloaded pediatric patients because most will require 
lifelong chelationtherapy
(15) 
Combined DFO (20 mg/kg/day, 2days/wk.) and DFX therapy (40 mg/kg/day, 7 
days per week) have shown significant and safe decline in mean serum ferritin (6337 
mcg\l) to (4850mcg\l) with no clear changes in hepatic or renal function. Combination 
therapy first practiced in major thalassemia by Anderson et al. They used combination 
Deferoxamine / Deferiprone and proposed several potential advantages with this 
regimen 
(17).
 Medicines with different properties and mechanisms may access different 
iron pools. The molecule of Deferasirox is small and can easily enter into cells and is 
able to transfer iron into plasma for Deferoxamine.
(18)
 In turkey the effectiveness of 
the alternating use of Deferiprone and Deferoxamine was initially studded, thisstudy 
serum ferritin decreased significantly. This regimen was associated with minimal 
adverse effect
.(19)
 
The major serious side effect of this regimen was creatinine rising which 
occurred in 21% of patients
(19)
.this problem was not encountered in our study, which 
may be explained by racial difference and small sample in this center. Our study 
reveal significant reduction of level of serum ferritin In both groups using combined 
or oral therapy, with maintains of acceptable safety and efficiency, although the rate 
of reduction was higher in patients on combined Deferoxamine-Deferasirox therapy. 
This study try to maintained faster and better declined in serum ferritin with 
maintained of best patients compliance and drug reliability, since we try to reduce the 
troublesome of subcutaneous injections of DFO together with simplicity with which 
the oral DFX characteristic
(20.21.22)
.This approach of therapy is a flexible regimen, 
which would allow the clinicians reduce the nightly Deferoxamine injections and 
increase the oral dose. The only disadvantage of this regimen is the absence of gap 
free iron chelator time. Combined regimen was associated with minimal adverse 
effect as it was showed by insignificant changes in liver enzymes, PT, BU and Serum 
creatinine.    
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It has been shown that simultaneous administration of DFO and DFX rapidly 
reduced systemic and myocardial iron, and provided an excellent control of the toxic 
labile plasma iron species without an increase in toxicity ,study done to evaluate the 
safety and efficacy of combined therapy with Deferasirox (DFX, 20-30 mg/kg daily) 
and Deferoxamine (DFO, 35-50 mg/kg on 3 days/week) in 22 patients with persistent 
iron overload or organ damage.
(22)
 
Serum ferritin may be unreliable for estimating body iron because vaso-
occlusive crises are associated with elevation of serum ferritin. However serum 
ferritin trends in between quantitative hepatic iron measurements can be useful, 
provided the serum ferritin tests are always carried out when the patients is in steady 
state
(23)
. Our study end with the result that ; although there was significant reduction 
in serum ferritin observed in all patients who chose both type of therapy , there was 
no significant side effect ,together it maintained renal function and liver enzymes with 
in the safe limit, in spite of these promising results there was significant difference in 
rate and degree of reduction of serum ferritin noticed inpatients on combined therapy. 
CONCLUSIONS:  
Combined Deferoxamine- deferasiraox therapy proved to be efficient and with 
insignificant negative effect on renal or hepatic function. The rate of reduction of 
serum ferritin is higher for patients on Deferoxamine-Deferasirox therapy ,with 
statistically significant variation. 
RECOMMENDATION: 
1. For treatments of iron overload in patients with SCD, Deferoxamine-Deferasiraox 
is safe and convenient with better patients compliance. 
2. Larger group of patients need to be restudied for better evaluation of combined 
Deferoxamine-Deferasirox therapy. 
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